Jubilant Pharmova Limited (JUBLPHARMA.NS)

INR 1085.05

(-0.42%)

Market Cap (In INR)

172.82 Billion

Revenue (In INR)

67.02 Billion

Net Income (In INR)

771 Million

Avg. Volume

885.74 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
465.0-1309.9
PE
-
EPS
-
Beta Value
1.562
ISIN
INE700A01033
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Priyavrat Bhartia MBA
Employee Count
-
Website
https://www.jubilantpharmova.com
Ipo Date
2002-07-01
Details
Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.